{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:31:19Z","timestamp":1748518279853},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Isavuconazole is a triazole antifungal agent for treatment of invasive aspergillosis and mucormycosis. At present, it is unclear whether a therapeutic drug monitoring (TDM) of isavuconazole would be necessary. The aim of the investigation was to validate a high-performance liquid chromatography (HPLC) assay for routine applications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>An HPLC assay for routine determination of isavuconazole in plasma has been adapted and validated. The assay used the reagents and HPLC column provided by the ChromSystems HPLC Kit for TDM of itraconazole, posaconazole, and voriconazole. Isocratic flow rate was set at 1.0 mL\/min. Detection was performed using a fluorescence detector with excitation wavelength set at 261 nm and emission wavelength set at 366 nm.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The assay was linear between 0.15 and 10 mg\/L with intraday and interday imprecision and accuracy &lt;10% (&lt;20% at lower limit of quantification). The method was applied to routine TDM of 7 patients after hematopoietic stem cell transplantation (n = 31 samples). In these patients, trough levels ranged from 0.45 to 3.06 mg\/L (median 1.44 mg\/L).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A robust and simple HPLC assay of isavuconazole in plasma for routine TDM applications is presented.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000524","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T21:12:00Z","timestamp":1531343520000},"page":"503-506","source":"Crossref","is-referenced-by-count":10,"title":["Validation of an Isavuconazole High-Performance Liquid Chromatography Assay in Plasma for Routine Therapeutic Drug Monitoring Applications"],"prefix":"10.1097","volume":"40","author":[{"given":"Silke C.","family":"Mueller","sequence":"first","affiliation":[{"name":"Center for Pharmacology and Toxicology, Institute of Clinical Pharmacology, University Medicine Rostock; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Karasch","sequence":"additional","affiliation":[{"name":"Center for Pharmacology and Toxicology, Institute of Clinical Pharmacology, University Medicine Rostock; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Lakner","sequence":"additional","affiliation":[{"name":"Center for Internal Medicine, Clinic for Hematology and Oncology, University Medicine Rostock, Rostock, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Wacke","sequence":"additional","affiliation":[{"name":"Center for Pharmacology and Toxicology, Institute of Clinical Pharmacology, University Medicine Rostock; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1517\/14656566.2015.1057500","article-title":"The \u201ccephalosporin era\u201d of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections","volume":"16","author":"Chitasombat","year":"2015","journal-title":"Expert Opin Pharmacother."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R6-20230814","first-page":"79","article-title":"Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections","volume":"9","author":"Donnelley","year":"2016","journal-title":"Infect Drug Resist."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampicin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jchromb.2012.01.015","article-title":"Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection","volume":"888","author":"Wissen","year":"2012","journal-title":"J Chromatogr B"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2017.01.036","article-title":"An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples","volume":"1046","author":"Toussaint","year":"2017","journal-title":"J Chromatogr B"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FTD.0000000000000438","article-title":"Reliable and easy-to-use liquid chromatography-tandem mass spectrometry method for simultaneous analysis of fluconazole, isavuconazole, itraconazole, hydroxy-itraconazole, posaconazole, and voriconazole in human plasma and serum","volume":"39","author":"Mueller","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.01276-09","article-title":"Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:17:23Z","timestamp":1692051443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000524","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}